Clinical trials: Head and Neck Cancers- Squamous Cell
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Mouth Neoplasms, Oral Cancers
Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.
- Conditions
- Mouth Neoplasms, Oral Cancers, Oral Squamous Cell Carcinoma (OSCC), Oral Squamous Cell Carcinomas
- Trial name
- SECOND N0 (NCT05774483)
- Testing
- Sentinel Node Biopsy, Limited Elective Neck Dissection
- Where
- 3 sites in India
- Volunteers
- 508 people
- Sponsor
- Tata Memorial Hospital
Esophageal Squamous Cell Carcinoma
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
This is a phase II, open label, two-centered study for evaluation of the addition of nivolumab and cetuximab after chemoradiation as a neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT04229459
- Testing
- Cisplatin, 5-FU, Radiation therapy
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Baruch Brenner
SCC - Squamous Cell Carcinoma, Upper Aero-digestive Tract (UADT) Neoplasm
Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide.
- Trial name
- CIRADOR (NCT06479070)
- Testing
- Blood samples
- Where
- 7 sites in France, Switzerland
- Volunteers
- 188 people
- Sponsor
- Institut de Cancérologie de Lorraine
Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
- Trial name
- NCT00210470
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Volunteers
- 27 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination…
- Trial name
- NCT05156970
- Testing
- Camrelizumab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation…
- Trial name
- NCT05894083
- Testing
- Surgery, Chemoradiation, Observation
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic…
- Trial name
- NCT04785820
- Testing
- Lomvastomig, Tobemstomig, Nivolumab
- Where
- 52 sites in Argentina, Brazil and 16 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
The purpose of this study is to investigate a new agent Axitinib in the treatment of head and neck cancer. This is a new drug that is given as a pill twice a day to treat cancer. This is one of the new, "smart" drugs.
- Trial name
- NCT01469546
- Testing
- Axitinib (AG-013736)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Cancer
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an open-label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03222440
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Squamous Cell of Head and Neck
Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients
The purpose of this study is to identify predictive and pharmacodynamic biomarkers of activity and efficacy of pre-operative Afatinib (BIBW2992) in untreated non-metastatic head and neck squamous cell carcinoma patients
- Trial name
- PREDICTOR (NCT01415674)
- Testing
- Afatinib
- Where
- 11 sites in France
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer, Cervical Cancer
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients…
- Conditions
- Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00019110
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
- Where
- 6 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
- Trial name
- NCT05317325
- Testing
- OCDC vaccine; NeoDC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Head and Neck Squamous Cell Carcinoma
INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
Elective nodal irradiation has been a longstanding standard-of-care in the management of mucosal squamous cell carcinoma of the head and neck.
- Trial name
- NCT03953976
- Testing
- Intensity modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Squamous Cell Carcinoma
Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma
This is a randomized phase 2 study on the impact of acupuncture on acute dysphagia in patients treated with radio-chemotherapy for head and neck squamous cell carcinoma
- Trial name
- ACP-HN (NCT05143268)
- Where
- 2 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Lorenzo Livi
Head and Neck Squamous Cell Carcinoma
Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients
This clinical trial studies the effect and underlying mechanisms of sleep and circadian rhythm factors on oral mucositis pain in head and neck cancer patients treated by chemoradiotherapy.
- Trial name
- NCT05099952
- Testing
- Biospecimen Collection, Counseling, Educational Intervention
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx
Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy…
- Trial name
- STELLAR (NCT05752149)
- Testing
- CRGD-ZW800-1
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Erasmus Medical Center
Esophageal Squamous Cell Carcinoma
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
This is a multicenter，single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous…
- Trial name
- QICE-ESCC (NCT07049185)
- Testing
- QL1706 Plus Celecoxib Group
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- Peking University Cancer Hospital & Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.